More than half of patients with early-stage non-small cell lung cancer (NSCLC) experience recurrent disease following definitive therapy. Targeted therapies have demonstrated significant and clinically meaningful benefit in EGFR-, ALK-, or RET-driven early-stage NSCLC. There are, however, no approved therapies for earl...
J. Chaft, Jay M. Lee, Suresh Senan et al.· Future Oncology· 0 citations
BACKGROUND
For patients with resected, ALK-positive non-small-cell lung cancer (NSCLC), adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in the global, phase 3, open-label, randomised ALINA trial. We report safety and health-related quality-of-life (HRQoL) outcomes from...
R. Dziadziuszko, J. S. Ahn, F. Barlesi et al.· The Lancet Oncology· 0 citations
INTRODUCTION
In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion.
METHODS
Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment c...
Yi-Long Wu, M. Majem, T. John et al.· Journal of Thoracic Oncology· 1 citation
In patients with NSCLC, in patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM, highlighting CD36 as a promising therapeutic target to limit the progression of LM.
Shou-Heng Lin, Kai Yin, M. Zheng et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
